Suppliers / Biophore India Pharmaceuticals

Biophore India Pharmaceuticals

India 672 employees Updated 9 July 2026

Biophore India Pharmaceuticals is an API manufacturer based in India. It holds 152 active US drug master files. Its filings concentrate with CDSCO (India) and MINSA (CR). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 26 April 2024 as NAI. Customs aggregates show $9.7M of exports covering 225 molecules to 34 destinations in 2025.

152
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
10
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 26 April 2024 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Visakhapatnam, India 3015941740

What they file, and where

Molecule Regulators Docs
Prochlorperazine US FDA 3
Asciminib US FDA 2
Cariprazine US FDA 2
Cladribine US FDA 2
Diatrizoate US FDA 2
Eliglustat US FDA 2
Etacrynic Acid US FDA 2
Iron Sucrose US FDA 2
Melphalan US FDA 2
Naphazoline US FDA 2
Show all 30 molecules on file
Olaparib US FDA 2
Phylloquinone US FDA 2
Suvorexant US FDA 2
Tafamidis US FDA 2
Tolvaptan US FDA 2
Triethylenetetramine US FDA 2
Viloxazine US FDA 2
Acrivastine US FDA 1
Alosetron US FDA 1
Aminocaproic Acid US FDA 1
Ataluren US FDA 1
Avatrombopag US FDA 1
Belinostat US FDA 1
Bempedoic Acid US FDA 1
Bendamustine US FDA 1
Bilastine US FDA 1
Bortezomib US FDA 1
Brexpiprazole US FDA 1
Calcium US FDA 1
Cannabidiol US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 8 None
MINSA (CR) 2 None
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $1.7M 17
2025 Not reported $9.7M 34
2024 Not reported $5.3M 31
2023 Not reported $5.2M 20

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Biophore India Pharmaceuticals comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 1 active litigation matter is on record.
  • The most recent inspection outcome was NAI, on 26 April 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts